SuperworthGRAIL price to book ratio GRAL
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 2.3×
- 2-year median
- 0.7×
- Against its 2-year history
- 97th
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 0.1× to 2.5×
- Peer median
- 4.3×
GRAIL's price to book ratio is 2.3× as of Oct 23, 2026.
That is above its 2-year median of 0.7×, higher than on 97% of days in the last 2 years.
Over that time it ranged from 0.1× in Sep 2024 to 2.5× in Oct 2026.
The median for 10 diagnostics and research stocks of a similar size is 4.3×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.3× | 0.7× | 2.5× |
| 2025 | 1.6× | 0.2× | 1.9× |
| 2024 | 0.3× | 0.1× | 0.3× |
Against its peers
Companies in Medical - Diagnostics & Research nearest GRAIL's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| GRALGRAIL | 2.3× |
| LNTHLantheus | 5.0× |
| BLLNBillionToOne | 9.5× |
| CAICaris Life Sciences | 15.3× |
| VCYTVeracyte | 2.8× |
| CDNACareDx | 8.4× |
| BIOBio-Rad Laboratories | 1.4× |
| RVTYRevvity | 2.5× |
| MEDPMedpace | 43.1× |
| LHLabcorp | 3.1× |
| DGXQuest Diagnostics | 3.6× |
| Peer median | 4.3× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on GRAIL
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.